The Food and Drug Administration (FDA) has approved the Dexcom G5 Mobile Continuous Glucose Monitoring (CGM) System, the first fully mobile real-time diabetes management device for adults and children ≥2 years of age. The approval of Dexcom G5 follows the G4 Platinum CGM with Share, which enables glucose monitoring on the Apple Watch.
Dexcom G5 CGM System has built-in wireless Bluetooth technology that sends vital glucose data directly to an app on iOS devices; Android access will come early next year. Users can choose up to five “followers” who will receive the user’s glucose information and alerts. It provides single digit MARD (mean absolute relative difference), customizable alerts, and a low glucose alarm (55mg/dL). Integration of the glucose monitoring data with Dexcom CLARITY, a cloud-based reporting software, allows for personalized trend analyses to improve diabetes management.
Dexcom G5 Mobile CGM System will be available late September 2015. Those who have purchased G4 Platinum with Share systems from August 1, 2015 until Dexcom G5 will be available will be eligible to upgrade to the G5 Mobile system at no cost.
For more information visit Dexcom.com.